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Carrier identification in newborn screening
In  1994,  the  UK  Clinical  Genetics  Society  published  a 
report in which it stated that ‘the working party would 
make a presumption against testing children to determine 
their  carrier  status,  where  this  would  be  of  purely 
reproductive  significance  to  the  child  in  the  future’[1]. 
The  following  year,  the  American  Society  of  Human 
Genetics and the American College of Medical Genetics 
issued a joint statement in which they came to the same 
conclusion: ‘If the medical or psychosocial benefits of a 
genetic test will not accrue until adulthood, as in the case 
of carrier status or adult-onset diseases, genetic testing 
generally should be deferred’ [2].
Neither of these statements considered the fact that the 
most common genetic screening program in pediatrics, 
newborn screening (NBS), was (or would soon) routinely 
identify carriers. NBS for phenylketonuria began in the 
1960s in both countries and hypothyroidism was added 
in the 1970s in the US and in 1981 in the UK. Both were 
conditions for which early treatment existed. Following 
the  discovery  that  penicillin  prophylaxis  would  reduce 
mortality in infants with sickle cell disease (SCD), a 1987 
National Institute of Health (USA) consensus conference 
recommended  universal  NBS  for  hemoglobinopathies 
[3]. By 1994, 42 US states were screening for SCD and 
other hemoglobin variants [4], and the UK would follow 
within  a  decade  [5].  Virtually  all  screening  methods 
identify individuals with both SCD and sickle cell trait 
(SCT, the heterozygous carrier state) [3].
In both countries, an early concern was what to do with 
the identification of carriers in NBS programs. In its 1994 
report,  Assessing  Genetic  Risks  [4],  the  US  Institute  of 
Medicine  (IOM)  stated  that  newborns  should  not  be 
screened for the purpose of determining carrier status, 
but that results obtained incidentally should be reported 
to the infant’s parents. The IOM recommended counsel-
ing and consent for NBS because of the routine identi-
fication of carriers [4].
The main argument to support voluntary consent for 
NBS is based on the great deference that our society gives 
to  parents  about  how  they  raise  their  children  [6,7]. 
Parents  are  given  wide  discretion  in  medical  decision-
making, with the threshold for state intervention based 
on whether a parent’s action is abusive or neglectful [6,7]. 
Given that the likelihood of a true positive NBS is rather 
low,  parental  refusal  does  not  fall  into  the  category  of 
abuse or neglect. The legitimacy of a mandatory program 
is further challenged as NBS expands beyond conditions 
for which early treatment is known to be highly effective 
[8]. In addition, there is growing parental concern about 
the  use  of  residual  blood  spots  for  research  when  the 
parents have not provided consent [9].
Carrier status and its health implications
Traditionally, carriers of autosomal recessive conditions 
were  presumed  to  be  healthy  and  carrier  status  was 
presumed  to  have  mainly  reproductive  implications. 
However, in the case of SCT, the data suggest otherwise. 
In a 1978 review, Sears [10] found convincing evidence 
that SCT was associated with hyposthenuria (decreased 
ability  to  concentrate  urine),  renal  hematuria  or 
bacteriuria (blood or bacteria in the urine), pyelonephritis 
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© 2010 BioMed Central Ltd(kidney inflammation) in pregnancy, and splenic infarc-
tion when exposed to hypoxia at high altitudes. Although 
Sears  [10]  enumerated  many  other  associations,  the 
evidence  was  too  anecdotal  to  make  any  valid  conclu-
sions. In a 2009 review, Tsaras et al. [11] found additional 
definitive associations between SCT and renal medullary 
cancer,  exercise-related  sudden  death  and  exertional 
rhabdomyolysis (muscle breakdown).
SCT  is  not  exceptional;  carriers  of  other  conditions 
have also been found to be at risk for health conditions. 
For example, 20 to 30% of female carriers of a dystrophin 
mutation associated with Duchenne muscular dystrophy 
develop cardiomyopathies [12], and fragile X pre-muta-
tion carriers are at risk for premature ovarian failure and 
fragile X ataxia syndrome [13]. What makes the example 
of SCT important, however, are the historical lessons to 
be learned about the unintended psychosocial harms that 
population  carrier  screening  caused  in  the  1970s  and 
1980s,  eroding  African  American  trust  in  the  medical 
community  [4,14].  Thus,  when  the  National  Collegiate 
Athletic Association (NCAA) announced in 2009 that it 
would require SCT testing of all college athletes [15], the 
Sickle Cell Disease Association of America opposed this 
policy  out  of  concern  that  identification  could  lead  to 
discrimination and stigma [16].
The  NCAA  policy  stems  from  the  resolution  of  a 
lawsuit with the family of Dale Lloyd II, a college athlete 
with  SCT  who  died  during  football  practice  [15].  The 
relationship  between  SCT  and  exercise-induced  death 
was first raised in military basic training in 1970 [17], and 
two large studies in the 1980s and 1990s confirmed that 
recruits  with  SCT  were  at  increased  risk  of  exercise-
induced death [18,19]. Minor changes in basic training 
programs, however, have been effective in reducing the 
number  of  deaths  from  SCT  in  basic  training  (Gary 
Crouch, personal communication). On the basis of these 
data,  the  military  no  longer  screens  recruits  for  SCT, 
which  makes  the  NCAA  policy  suspect,  particularly 
given that there is no consensus on how this information 
is to be used by the universities where these athletes play.
The  need  for  the  NCAA  policy,  however,  should  be 
short-lived because by 2020 all college athletes with SCT 
will have been identified in newborn screening. However, 
it  is  not  certain  that  these  youngsters  will  know  their 
results.  In  2008,  Kavanaugh  et  al.  [20]  showed  that  at 
least two programs did not report SCT and three states 
informed  only  the  families  but  not  their  health  care 
providers.  But  even  in  states  in  which  parents  and 
providers are supposed to be informed, this is not always 
happening [20]. In the UK, legislation was passed in 2000 
to  create  a  national  linked  registry  of  prenatal  and 
neonatal  SCT  to  ensure  that  carrier  status  data  are 
accessible  regardless  of  how  and  when  they  are 
determined [21].
Adolescent carrier identification
In  2001,  the  American  Academy  of  Pediatrics  (AAP) 
published a statement [22] on genetic testing in children. 
Like the professional statements of the 1990s, the AAP 
did  ‘not  support  the  broad  use  of  carrier  testing  or 
screening in children or adolescents’ [22]. However, the 
AAP noted that carrier testing may be appropriate for the 
pregnant adolescent or the adolescent who is planning a 
pregnancy [22]. In other countries, the practice of carrier 
identification  of  adolescents  for  reproductive  planning 
purposes  is  more  routine.  There  have  been  various 
population-based screening programs of adolescents, for 
Tay Sachs disease, cystic fibrosis and hemoglobinopathies, 
in Canada, Australia and the Middle East. Many of these 
programs  were  implemented  in  the  school  setting 
because  it  offers  the  opportunity  to  capture  a  large 
percentage  of  adolescents,  and  the  information  is  well 
retained [23]. Concerns, however, have been raised that 
the school setting may not be ideal for ensuring privacy 
and  confidentiality  [23].  School-based  programs  also 
raise questions about the voluntariness of consent. The 
consent  issues  may  be  even  more  complicated  if  such 
programs were to be replicated in the US, where school-
based screening may require parental permission.
Data  show  that  many  parents  support  the  testing  of 
their children for carrier status before the legal age of 
majority  for  a  wide  array  of  conditions,  including 
conditions  for  which  population-based  screening  may 
not  be  economically  justifiable  [24].  The  arguments  to 
support carrier testing of minors are: (1) it may be easier 
to incorporate this information into their life plans; (2) it 
reduces uncertainty and the resentment expressed when 
the  information  is  delayed;  and  (3)  the  parental  moral 
right,  or  even  moral  obligation,  to  know  their  child’s 
genetic risks [24]. A survey of social networkers in the US 
found that 6% had used the services of a personal genome 
testing (PGT) company and an additional 64% indicated 
that they would consider using them in the future, with 
the  majority  interested  in  carrier  testing  of  someone 
other than themselves, including their progeny [25]. The 
respondents  were  interested  in  testing  despite  the  fact 
that less than half were confident that they understood 
the risks and benefits of PGT [25]. Tabor and Kelley [26] 
suggest that direct-to-consumer (DTC) PGT companies 
should  accept  some  moral  responsibility  to  educate 
parents  about  the  risks  and  benefits  of  testing  their 
children,  to  encourage  parents  to  opt  out  of  receiving 
carrier test data for rare genetic traits ‘particularly if they 
have no reason to be concerned about increased family 
risk’,  and  to  provide  genetic  counseling  to  avoid  mis-
understandings.  Three  additional  issues  have  not  been 
adequately addressed with respect to DTC PGT. First is 
whether there is an obligation by parents or DTC PGT 
companies to ensure that the minors have access to this 
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reach adulthood. Second, empirical data are needed on 
how to ensure that the carrier information is transferred 
in a way that promotes understanding and minimizes the 
harms  that  such  information  may  cause.  Third, 
conceptual  analyses  are  needed  to  examine  whether 
adolescents should be able to seek DTC PGT alone or 
whether  parental  permission  should  be  required,  and 
how this could be enforced.
Conclusions
Current policy statements on carrier testing of minors 
focus on why parents want this reproductive information 
and do not fully consider other health implications that 
carrier  status  may  confer,  nor  the  value  of  carrier 
identification for the maturing minors themselves. The 
statements also fail to provide an analytical framework 
regarding whose consent is needed. Currently, there is no 
consensus on whether minors should be able to consent 
for  themselves  for  carrier  testing  or  whether  parental 
permission is necessary, although neonates are routinely 
identified  through  NBS  without  any  consent.  There  is 
also  no  consensus  about  the  appropriate  venues  for 
carrier testing of minors - whether it should be restricted 
to the clinics or permitted in schools or at home. Policy 
recommendations about carrier testing of children need 
to be re-examined.
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